Use of pimecrolimus cream in disorders other than atopic dermatitis

Journal of Cutaneous Medicine and Surgery

Volumn 12, Issue 1, 2008, Pages 17-26

  Day, Isaiah ^a   Lin, Andrew N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL; CLOBETASOL PROPIONATE; FLUTICASONE PROPIONATE; HYDROCORTISONE ACETATE; MINOCYCLINE; MOMETASONE FUROATE; PIMECROLIMUS; PLACEBO; PREDNISONE; STEROID; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ABSENCE OF SIDE EFFECTS; ACNE VULGARIS; ALLERGY TEST; ASTEATOTIC ECZEMA; ATOPIC DERMATITIS; BALANITIS; BEHCET DISEASE; CLINICAL TRIAL; CONTACT DERMATITIS; CREAM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA ANNULARE CENTRIFUGUM; FOLLICULITIS; GRAFT VERSUS HOST REACTION; HAND DISEASE; HUMAN; LICHEN; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LICHEN STRIATUS; NETHERTON DISEASE; ORAL LICHEN; PITYRIASIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; ROSACEA; SCABIES; SEBORRHEIC DERMATITIS; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VITILIGO; VULVA PRURITUS;

ADMINISTRATION, TOPICAL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; OINTMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES; TACROLIMUS;

EID: 40549105096     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.07026     Document Type: Review

References (88)

1. Lin AN. Topical calcineurin inhibitors. In: Wolverton S, editor. Systemic drug therapy in dermatology. London, UK: Elsevier; 2007. p. 671-90.
2. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002;46:228-41.
3. Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-8.
4. Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006;142:1138-43.
5. Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6.
6. Mrowietz U, Wustlich S, Hoexter G, et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003;83:351-3.
7. Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol 2004;18:742-3.
8. Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J 2006;12:7.
9. Ahn SJ, Oh SH, Chang SE, et al. A case of infantile psoriasis with Pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy. J Eur Acad Dermatol Venereol 2006;20:1332-4.
10. Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006;142:1066-7.
11. Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007;57:257-64.
12. Rigopoulos D, Ioannides D, Kalogeromitros D, et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004;151:1071-5.
13. Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res 2004;30:191-5.
14. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermatol 2006;54:1083-8.
15. Cunha PR. Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta Derm Venereol 2006;86:69-70.
16. Gorman CR, White SW. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch Dermatol 2005;141:1168.
17. Crutchfield CE III. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 2002;70:207-3.
18. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 2003;9:13.
19. Belsito DV, Fowler JF Jr, Marks JG, Jr, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004;73:31-8.
20. Cherill R, Toftte S, MacNaul R, et al. SDZ ASM 981 1% cream is effective in the treatment of chronic irritant hand dermatitis. J Eur Acad Dermatol Venereol 2000;14:128.
21. Thaci D, Steinmeyer K, Ebelin ME, et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 2003;207:37-42.
22. Bukhari IA. Successful treatment of chronic persistent vesicular hand dermatitis with topical pimecrolimus. Saudi Med J 2005;26: 1989-91.
23. Schurmeyer-Horst F, Luger TA, Bohm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007;214:99-100.
24. Atwa M. Efficacy and safety of pimecrolimus (ASM 981) cream 1% in the treatment of vitiligo. J Am Acad Dermatol 2005;52:P168.
25. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006;4:942-6.
26. Seckin D, Eryilmaz ABM. A double-blind, randomized trial of 1% pimecrolimus versus 0.05% clobetasol propionate for the treatment of vitiligo. J Am Acad Dermatol 2007;56:AB170.
27. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15:88-91.
28. Boone B, Ongenae K, Van Geel N, et al. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007;17:55-61.
29. Mayoral FA, Gonzalez C, Shah NS, Arciniegas C. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003;207:322-3.
30. Mayoral FA, Stavisky H, McCormick CL. A retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo. J Am Acad Dermatol 2006;54:AB194.
31. Schulz P, Bunselmeyer B, Brautigam M, Luger TA. Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007;21:90-4.
32. Bhardwaj SS, Jaimes JP, Liu A, Warshaw EM. A double-blind randomized placebo-controlled pilot study comparing topical immunomodulating agents and corticosteroids for treatment of experimentally induced nickel contact dermatitis. Dermatitis 2007; 18:26-31.
33. Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42:349-50.
34. Amrol D, Keitel D, Hagaman D, Murray J. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol 2003;91:563-6.
35. Black RJ. Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. Clin Exp Dermatol 2005;30:91-2.
36. Spergel JM, Nurse N, Taylor P, Parneix-Spake A. Effect of topical pimecrolimus on epicutaneous skin testing. J Allergy Clin Immunol 2004;114:695-7.
37. Weissenbacher S, Traidl-Hoffmann C, Eyerich K, et al. Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. Int Arch Allergy Immunol 2006;140:239-44.
38. Tan JK, Morneau K, Fung K. Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris. J Am Acad Dermatol 2005;52:738-9.
39. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005;4:147-50.
40. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005;152:396-9.
41. Cunha PR, Rossi AB. Pimecrolimus cream 1% is effective in a case of granulomatous rosacea. Acta Derm Venereol 2006;86:71-2.
42. Lubbe J, Stucky L, Saurat JH. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology 2003;207:204-5.
43. Nissi R, Eriksen H, Risteli J, Niemimaa M. Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest 2007;63:151-4.
44. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J Reprod Med 2004;49:778-80.
45. Boms S, Gambichler T, Freitag M, et al. Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatol 2004; 4:14.
46. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004;17:35-7.
47. Arican O, Ciralik H, Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J Dermatol 2004;31:1014-7.
48. Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005;44:1564-8.
49. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004;51:407-10.
50. Zabawski E. Treatment of cutaneous lupus with Elidel. Dermatol Online J 2002;8:25.
51. Swift JC, Rees TD, Plemons JM, et al. The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J Periodontal 2005;76:627-35.
52. Esquivel-Pedraza L, Fernandez-Cuevas L, Ortiz-Pedroza G, et al. Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br J Dermatol 2004;150:771-3.
53. Dissemond J, Schroter S, Franckson T, et al. Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. Br J Dermatol 2004;150:782-4.
54. Cedro M, Chaudhry S, Porter S. OC10 topical pimecrolimus for the treatment of erosive oral lichen planus. Oral Dis 2006;12:11.
55. Lonsdale-Eccles AA, Velangi S. Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br J Dermatol 2005;153:390-4.
56. Kose O, Dinc A, Kurumlu Z. The efficacy of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of the genital ulcers in Behcet's disease. J Am Acad Dermatol 2007;56: AB42.
57. Davatchi F. New and innovative therapies for Behcet's disease. APLAR J Rheumatol 2004;7:141-5.
58. Fujita W. An exploratory study to determine the efficacy of 1% pimecrolimus cream in the treatment of pityriasis alba. J Am Acad Dermatol 2005;52:P46.
59. Barr J, Friedman A, Blawin H. Use of imiquimod and pimecrolimus cream in the treatment of acne keloidalis nuchae. J Am Acad Dermatol 2005;52:P64.
60. Goldstein AT, Parneix-Spake A. A preliminary open-label trial of topical pimecrolimus cream 1% for the treatment of vulvar lichen simplex chronicus. J Am Acad Dermatol 2006;54:AB80.
61. Sarifakioglu E, Gumus II. Efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus: a prospective case series - a non-controlled, open-label study. J Dermatolog Treat 2006;17:276-8.
62. Bjerke JR, Haug S. Efficacy of pimecrolimus cream versus placebo in chronic ear eczema: a randomized clinical trial. J Am Acad Dermatol 2006;54:AB93.
63. Djalilia HR, Memar O. Topical pimecrolimus 1% for the treatment of pruritic external auditory canals. Laryngoscope 2006;116:1809-12.
64. Ziemer M, Gruhn B, Thiele JJ, Elsner P. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J Am Acad Dermatol 2004;50:946-8.
65. Schmook T, Kraft J, Benninghoff B, et al. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant 2005;36:87-8.
66. Campione E, Patemo EJ, Diluvio L, Bianci L. Treatment of disfiguring chronic graft-versus-host disease in a child with topical pimecrolimus. J Am Acad Dermatol 2007;56:AB54.
67. Kus S, Ince U. Lichen striatus in an adult patient treated with pimecrolimus. J Eur Acad Dermatol Venereol 2006;20:360-1.
68. Saez-Rodriguez M, Rodriguez-Martin M, Carnerero-Rodriguez A, et al. Lichen striatus in an adult successfully treated with pimecrolimus cream. J Eur Acad Dermatol Venereol 2006;20: 1140-1.
69. Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005; 153:1067-8.
70. Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-87.
71. Thaci D, Schwwanner PS, Spieth K, et al. Comel-Netherton syndrome: a case treated with topical pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2004;18:160.
72. Yan A, Shah K, Kubrak D, Pameix-Spake A. A pilot study of the efficacy and safety of pimecrolimus 1% cream in the treatment of Netherton syndrome: interim results. J Am Acad Dermatol 2007; 56:AB153.
73. Rodriguez-Martin M, Saez-Rodriguez M, Carnerero-Rodriguez A, et al. Treatment of perioral dermatitis with topical pimecrolimus. J Am Acad Dermatol 2007;56:529-30.
74. Lim SJ, Love EW. Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus. J Drugs Dermatol 2004;3:563-4.
75. Lee HW, Lee MW, Choi JH, et al. Annular elastolytic giant cell granuloma in an infant: improvement after treatment with oral tranilast and topical pimecrolimus. J Am Acad Dermatol 2005;53: S244-6.
76. de Almeida HL Jr, Oliveira Filho UL. Topical pimecrolimus is an effective treatment for balanitis circinata erosiva. Int J Dermatol 2005;44:888-9.
77. Bohm M, Bonsmann G, Luger TA. Resolution of lichen aureus in a 10-year-old child after topical pimecrolimus. Br J Dermatol 2004; 151:519-20.
78. Rigopoulos D, Prantsidis A, Christofidou E, et al. Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br J Dermatol 2005;152:1364-5.
79. Sulit DJ, Harford R, O'Neill JT. Discrete papular form of lichen myxedematosus: a case report and review of the literature. Cutis 2005;75:105-12.
80. Almeida HL Jr. Treatment of steroid-resistant nodular scabies with topical pimecrolimus. J Am Acad Dermatol 2005;53:357-8.
81. Pock L, Svrckova M, Machackova R, Hercogova J. Pimecrolimus is effective in Fox-Fordyce disease. Int J Dermatol 2006;45:1134-5.
82. Hafner C, Hohenleutner U, Babilas P, et al. Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology 2006;213:163-5.
83. Ertam I, Ertekin B, Unal I, Alper S. Granuloma faciale: is it a new indication for pimecrolimus? A case report. J Dermatolog Treat 2006;17:238-40.
84. Larangeira de Almeida H Jr. Successful treatment of chronic actinic dermatitis with topical pimecrolimus. Int J Dermatol 2005; 44:343-4.
85. Lee HW, Jeong YI, Choi JC, et al. Two cases of telangiectasia macularis eruptiva perstans demonstrated by immunohistochemistry for c-kit (CD 117). J Dermatol 2005;32:817-20.
86. Vereecken P, Pirard D, Petein M, Heenen M. Efficacy of pimecrolimus 1% cream for the treatment of erythema anuulare centrifugum: a case report. J Eur Acad Dermatol Venereol 2004;18: 161.
87. Tzung TY, Wu JC. Topical calcineurin inhibitors in treating Jessner's lymphocytic infiltration of the skin: report of a case. Br J Dermatol 2005;152:383-4.
88. Rho N-K, Kim B-J. Eosinophilic pustular folliculitis: successful treatment with topical pimecrolimus. Clin Exp Dermatol 2006;32: 108-9.